High Performance Wearable Ultrasound as a Human-Machine Interface for Wrist and Hand Kinematic Tracking.

Objective: Non-invasive human machine interfaces (HMIs) have high potential in medical, entertainment, and industrial applications. Traditionally, surface electromyography (sEMG) has been used to track muscular activity and infer motor intention. Ultrasound (US) has received increasing attention as an alternative to sEMG-based HMIs.

Small Fiber Neuropathy Triggered by COVID-19 Vaccination: Association with FGFR3 Autoantibodies and Improvement during Intravenous Immunoglobulin Treatment.

Multiple case series have demonstrated the emergence of small fiber neuropathy following acute coronavirus disease 2019 (COVID-19) infections. Further, one large case supports that the COVID-19 vaccine has been reported to result in small fiber neuropathy. We report a case of a patient with confirmed small fiber neuropathy post-COVID-19 vaccination with positive FGFR3 antibodies.

Simultaneous and proportional control of wrist and hand degrees of freedom with kinematic prediction models from high-density EMG.

To improve intuitive control and reduce training time for active upper limb prostheses, we developed a myocontrol system for 3 degrees of freedom (DoFs) of the hand and wrist. In an offline study, we systematically investigated movement sets used to train this system, to identify the optimal compromise between training time and performance. High-density surface electromyography (HDsEMG) and optical marker motion capture were recorded concurrently from the lower arms of 8 subjects performing a series of wrist and hand movements activating DoFs individually, sequentially, and simultaneously.

Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis.

Background: For small molecules such as teriflunomide, used to treat relapsing multiple sclerosis (MS), that are potentially embryotoxic, there is a theoretical risk of transmission of the medication from males on the drug to female sexual partners. However, that risk has been undefined up to now.

Methods: Teriflunomide concentrations were assayed concomitantly in ten sexually active couples, not using barrier methods of contraception, in whom the male partner with MS was on treatment with teriflunomide 14 mg daily for at least two months.